Cargando…

Involvement of adiponectin in the pathogenesis of dystrophinopathy

BACKGROUND: The hormone adiponectin (ApN) is decreased in the metabolic syndrome, where it plays a key pathogenic role. ApN also exerts some anti-inflammatory effects on skeletal muscles in mice exposed to acute or chronic inflammation. Here, we investigate whether ApN could be sufficiently potent t...

Descripción completa

Detalles Bibliográficos
Autores principales: Abou-Samra, Michel, Lecompte, Sophie, Schakman, Olivier, Noel, Laurence, Many, Marie C., Gailly, Philippe, Brichard, Sonia M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528853/
https://www.ncbi.nlm.nih.gov/pubmed/26257862
http://dx.doi.org/10.1186/s13395-015-0051-9
_version_ 1782384715671535616
author Abou-Samra, Michel
Lecompte, Sophie
Schakman, Olivier
Noel, Laurence
Many, Marie C.
Gailly, Philippe
Brichard, Sonia M.
author_facet Abou-Samra, Michel
Lecompte, Sophie
Schakman, Olivier
Noel, Laurence
Many, Marie C.
Gailly, Philippe
Brichard, Sonia M.
author_sort Abou-Samra, Michel
collection PubMed
description BACKGROUND: The hormone adiponectin (ApN) is decreased in the metabolic syndrome, where it plays a key pathogenic role. ApN also exerts some anti-inflammatory effects on skeletal muscles in mice exposed to acute or chronic inflammation. Here, we investigate whether ApN could be sufficiently potent to counteract a severe degenerative muscle disease, with an inflammatory component such as Duchenne muscular dystrophy (DMD). METHODS: Mdx mice (a DMD model caused by dystrophin mutation) were crossed with mice overexpressing ApN in order to generate mdx-ApN mice; only littermates were used. Different markers of inflammation/oxidative stress and components of signaling pathways were studied. Global force was assessed by in vivo functional tests, and muscle injury with Evans Blue Dye (EBD). Eventually, primary cultures of human myotubes were used. RESULTS: Circulating ApN was markedly diminished in mdx mice. Replenishment of ApN strikingly reduced muscle inflammation, oxidative stress, and enhanced the expression of myogenic differentiation markers along with that of utrophin A (a dystrophin analog) in mdx-ApN mice. Accordingly, mdx-ApN mice exhibited higher global force and endurance as well as decreased muscle damage as quantified by curtailed extravasation of EBD in myofibers. These beneficial effects of ApN were recapitulated in human myotubes. ApN mediates its protection via the adiponectin receptor 1 (AdipoR1, the main ApN receptor in muscle) and the AMPK-SIRT1-PGC-1α signaling pathway, leading to downregulation of the nuclear factor kappa B (NF-κB) and inflammatory genes, together with upregulation of utrophin. CONCLUSIONS: Adiponectin proves to be an extremely powerful hormone capable of protecting the skeletal muscle against inflammation and injury, thereby offering novel therapeutic perspectives for dystrophinopathies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13395-015-0051-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4528853
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45288532015-08-08 Involvement of adiponectin in the pathogenesis of dystrophinopathy Abou-Samra, Michel Lecompte, Sophie Schakman, Olivier Noel, Laurence Many, Marie C. Gailly, Philippe Brichard, Sonia M. Skelet Muscle Research BACKGROUND: The hormone adiponectin (ApN) is decreased in the metabolic syndrome, where it plays a key pathogenic role. ApN also exerts some anti-inflammatory effects on skeletal muscles in mice exposed to acute or chronic inflammation. Here, we investigate whether ApN could be sufficiently potent to counteract a severe degenerative muscle disease, with an inflammatory component such as Duchenne muscular dystrophy (DMD). METHODS: Mdx mice (a DMD model caused by dystrophin mutation) were crossed with mice overexpressing ApN in order to generate mdx-ApN mice; only littermates were used. Different markers of inflammation/oxidative stress and components of signaling pathways were studied. Global force was assessed by in vivo functional tests, and muscle injury with Evans Blue Dye (EBD). Eventually, primary cultures of human myotubes were used. RESULTS: Circulating ApN was markedly diminished in mdx mice. Replenishment of ApN strikingly reduced muscle inflammation, oxidative stress, and enhanced the expression of myogenic differentiation markers along with that of utrophin A (a dystrophin analog) in mdx-ApN mice. Accordingly, mdx-ApN mice exhibited higher global force and endurance as well as decreased muscle damage as quantified by curtailed extravasation of EBD in myofibers. These beneficial effects of ApN were recapitulated in human myotubes. ApN mediates its protection via the adiponectin receptor 1 (AdipoR1, the main ApN receptor in muscle) and the AMPK-SIRT1-PGC-1α signaling pathway, leading to downregulation of the nuclear factor kappa B (NF-κB) and inflammatory genes, together with upregulation of utrophin. CONCLUSIONS: Adiponectin proves to be an extremely powerful hormone capable of protecting the skeletal muscle against inflammation and injury, thereby offering novel therapeutic perspectives for dystrophinopathies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13395-015-0051-9) contains supplementary material, which is available to authorized users. BioMed Central 2015-08-07 /pmc/articles/PMC4528853/ /pubmed/26257862 http://dx.doi.org/10.1186/s13395-015-0051-9 Text en © Abou-Samra et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Abou-Samra, Michel
Lecompte, Sophie
Schakman, Olivier
Noel, Laurence
Many, Marie C.
Gailly, Philippe
Brichard, Sonia M.
Involvement of adiponectin in the pathogenesis of dystrophinopathy
title Involvement of adiponectin in the pathogenesis of dystrophinopathy
title_full Involvement of adiponectin in the pathogenesis of dystrophinopathy
title_fullStr Involvement of adiponectin in the pathogenesis of dystrophinopathy
title_full_unstemmed Involvement of adiponectin in the pathogenesis of dystrophinopathy
title_short Involvement of adiponectin in the pathogenesis of dystrophinopathy
title_sort involvement of adiponectin in the pathogenesis of dystrophinopathy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528853/
https://www.ncbi.nlm.nih.gov/pubmed/26257862
http://dx.doi.org/10.1186/s13395-015-0051-9
work_keys_str_mv AT abousamramichel involvementofadiponectininthepathogenesisofdystrophinopathy
AT lecomptesophie involvementofadiponectininthepathogenesisofdystrophinopathy
AT schakmanolivier involvementofadiponectininthepathogenesisofdystrophinopathy
AT noellaurence involvementofadiponectininthepathogenesisofdystrophinopathy
AT manymariec involvementofadiponectininthepathogenesisofdystrophinopathy
AT gaillyphilippe involvementofadiponectininthepathogenesisofdystrophinopathy
AT brichardsoniam involvementofadiponectininthepathogenesisofdystrophinopathy